D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTCgynaecological cancer co-operative group study

Between March and September 1988, 74 patients with progressive ovarian canc er after prior platinum-based therapy were treated with the luteinizing hor mone-releasing hormone (LHRH) agonist Triptorelin (Decapeptyl(R)). Treatmen t consisted of i.m. injection of 3.75 mg of microencapsulated Triptorelin o n days 1, 8 and 28 followed by 4-weekly injections until tumor progression. No objective responses were observed. Eleven out of 68 evaluable patients (16%) had stable disease. The median progression-free survival was 5 months in patients with disease stabilization and 2 months for all evaluable pati ents. The median survival for patients with disease stabilization was 17 mo nths, whereas for all patients it was 4 months. The treatment was well tole rated; the only reported adverse events were incidental hot flushes. This s tudy showed that the LHRH agonist Triptorelin has only modest efficacy in p atients pretreated with platinum-containing chemotherapy. [(C) 2001 Lippinc ott Williams & Wilkins.].